Cancer remains among the leading causes of death worldwide. This scenario urges the translation of scientific research into clinical benefits to the patients.
Effective therapies persist a challenge to be addressed. Our purpose is to improve the outcome of cancer patients by personalizing the drug delivery system.
18 million cases in 2018. 1 in 6 results in death
Costs of cancer in 2010 was estimated at approximately US$ 1.16 trillion
Global oncology therapeutics is expected increase 10-13% over the next 5 years.
Oncology therapeutic medicines are expected to reach $200 billion by 2022
A targeted delivery system
Our personalized molecules are design to specifically identify cancer cells and thus deliver with precision therapeutic interventions. Our approach is based on the technology of aptamers, being efficient, scalable and cheaper than those of other therapeutic classes such as monoclonal antibodies and antibody-drug conjugates, as also cellular and gene therapies.
Making science available
We work on the development and marketing of a new class of personalized therapies. Key elements of our strategy are the collaboration with universities, private companies and hospitals to accelerate the translation of our expertise into improvements on clinical outcomes for cancer patients.
Industrialize synthetic molecules to advance and scale our platform;
Strengthen and expand our intellectual property to protect our platform;
Work in collaboration with universities and private companies to accelerate the development technology.
Or follow us on social platform
© 2019 Bioptamers